Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Argon + helium refers to the combination of gases used in advanced cryosurgical systems, commonly known as the **argon-helium knife** or **lancet**. This technology leverages the Joule-Thomson effect to achieve rapid, targeted tissue destruction. High-pressure argon gas is released through a cryoprobe to induce extreme cooling (reaching temperatures between -140°C and -190°C), which causes the formation of intra- and extracellular ice crystals, leading to mechanical cell rupture and microvascular stasis. Subsequently, high-pressure helium gas is used to rapidly warm the probe (thawing), a process that further disrupts cell membranes and ensures complete necrosis of the targeted tumor tissue. This modality is primarily utilized for the percutaneous or intraoperative ablation of solid tumors, including non-small cell lung cancer (NSCLC), liver cancer, and prostate cancer, particularly in patients who are not suitable candidates for conventional surgical resection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on argon + helium.